Long-term prognostic value of PCNA labeling index in primary operable breast cancer

Oncology Reports

Volumn 5, Issue 3, 1998, Pages 641-644

  Horiguchi, Jun ^a   Iino, Yuichi ^a   Takei, Hiroyuki ^a   Maemura, Michio ^a   Takeyoshi, Izumi ^a   Yokoe, Takao ^a   Ohwada, Susumu ^a   Oyama, Tetsunari ^a   Nakajima, Takashi ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Prognosis; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 13144253168     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.3.641     Document Type: Article

References (22)

1. Muss HB, Kute TE, Case D, Smith LR, Booher C, Long R, Kammire L, Gregory B and Brockschmidt JK; The relationship of flow cytometry to clinical and biologic characteristics in women with node-negative primary breast cancer. Cancer 64: 1894-1900, 1989.
2. O'Reilly SM, Camplejohn DM, Barnes DM, Millis RR, Rubens RD and Richards MA: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8: 2040-2046, 1990.
3. Clark GM, Dressler LG, Owens MR, Pounds C, Oldaker T and McGuire WL: Prediction of relapse or survival in patients with node negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989.
4. Meyer JS, Nauert J, Koehm S and Hughes J: Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling. J Histochem Cytochem 37: 1449-1454, 1989.
5. Kamel OW, Fraklin WA, Ringus JC and Meyer JS: Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 134: 107-113, 1989.
6. Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Marin S, Alhava E and Syrjaenen K: Mitotic indexes as prognostic factors in female breast cancer. J Cancer Res Clin Oncol 118: 75-81, 1992.
7. Tahan SR, Neuberg DS, Dieffenbach A and Yacoub L: Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 71: 3552-3559, 1993.
8. Horiguchi J, Iino Y, Takei H, Morishita Y and Nakajima T: Expression of proliferating cell nuclear antigen in invasive ductal carcinoma of the breast. Jpn J Clin Oncol 24: 79-84, 1994.
9. Weikel W, Beck T, Mitze M and Knapstein PG: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149-154, 1991.
10. Pierga J-Y, Leroyer A, Viehl P, Mosseri S, Chevillard S and Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37: 57-64, 1996.
11. Cattoretti G, Becker M, Key G, Duchrow M, Schluler C, Galle J and Gerdes J: Monoclonal antibodies against recombinant part of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992.
12. Kurki P, Ogata K and Tan EM: Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J Immunol Methods 109: 49-59, 1988.
13. Visscher DW, Wykes S, Kubus J and Crissman JD: Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer. Breast Cancer Res Treat 22: 111-118, 1992.
14. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Palma PD and Barbareschi M: PCNA and Ki67 expression in breast carcinoma: Correlations with clinical and biological variables. J Clin Pathol 45: 416-419, 1992.
15. Sheen CSM, Eng HL, Chou FF and Chen WJ: The prognostic significance of proliferating cell nuclear antigen in patients with lymph node-positive breast cancer. Arch Surg 132: 264-267, 1997.
16. Tabbane F, Bahi J, Rahal K, El-May A, Riahi M, Cammoun M, Hechiche M, Jaziri M and Mourali N: Inflammatory symptoms in breast cancer. Correlations with growth rate, clinicopathologic variables, and evolution. Cancer 64: 2081-2089, 1989.
17. Brekelmans CT, van Gorp JM, Peeters PH and Collette HJ: Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78: 1220-1228, 1996.
18. Veronese SM and Gambacorta M: Detection of Ki-67 proliferation rate in breast cancer: correlation with clinical and pathologic features. Am J Clin Pathol 95: 30-34, 1991.
19. Sahin AA, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN and Ayala AG: Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68: 549-557, 1991.
20. Haerslev T, Jacobsen GK and Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37: 101-113, 1996.
21. Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello Q, Benetti F, Nortilli R, Turazza M and Cetto GL: Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat 38: 289-297, 1996.
22. Aaltomaa S, Lipponen P and Syrjanen K: Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. Anticancer Res. 12: 1281-1286, 1992.